ΙκΒ Kinase Α Is Required for Development and Progression of KRAS-mutant Lung Adenocarcinoma.

Cancer Research - United States
doi 10.1158/0008-5472.can-17-1944
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Coxsackievirus Type B3 Is a Potent Oncolytic Virus Against KRAS-Mutant Lung Adenocarcinoma

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2019English

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2015English

Inhibitor of Differentiation-1 (Id1) Sustains Mutant KRAS-driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Cancer Research
Cancer ResearchOncology
2018English

Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 Kinase in KRAS -Mutant Lung Cancer

Cancer Discovery
Oncology
2013English

P2.01-09 Targetable Genomic Alterations in KRAS Mutant Lung Adenocarcinoma by Targeted Next Generation Sequencing

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Growth Inhibition of KRAS‑�and EGFR‑mutant Lung Adenocarcinoma by Cosuppression of STAT3 and the SRC/ARHGAP35 Axis

Oncology Reports
MedicineCancer ResearchOncology
2018English

Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2014English

ASAP3 Is a Downstream Target of HIF-1α and Is Critical for Progression of Lung Adenocarcinoma

OncoTargets and Therapy
OncologyPharmacology
2019English

Targeting Oncogenic Protein Kinase Cι for Treatment of Mutant KRAS LADC

Small GTPases
BiochemistryCell Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy